Chen Albert C, Bonnen Mark D, Mok Henry
Department of Radiation Oncology, Baylor College of Medicine, Houston, TX, USA.
Br J Radiol. 2017 Apr;90(1072):20160922. doi: 10.1259/bjr.20160922. Epub 2017 Feb 9.
Metastatic spinal cord compression (MSCC) is an oncologic emergency that often warrants emergent treatment; but, it is unclear whether radiation treatment (RT) can be optimally managed from an offsite radiotherapy facility.
Patient charts from consecutive patients with MSCC who were treated with radiotherapy alone at either an onsite hospital radiation department (from 2008 to 2012) or an offsite radiotherapy centre (2012-2015) were reviewed. Patient clinical parameters were compared across groups with either the χ test or Fisher's exact test, while survival curves were compared with the log-rank test. The primary end points were ambulatory rate over time, overall survival and cancer-specific survival.
A total of 45 patients were identified, with 19 patients treated onsite in the hospital department and 26 patients treated at the offsite radiotherapy centre with median follow-up of 42 days vs 48.5 days, respectively. The ambulatory rate over time, overall survival and cancer-specific survival were not significantly different between the two eras. Patients treated in-hospital were more likely to start treatment the same day as the consult ("sim and treat") (79% vs 27%, p = 0.006) and were more likely to not complete treatment (26% vs 4%, p = 0.029) as compared with those treated in the offsite centre.
Patients with MSCC can be feasibly treated at an offsite radiotherapy centre with outcomes similar to those treated in-hospital. Advances in knowledge: This is the first study in literature to compare outcomes between onsite and offsite RT of MSCC.
转移性脊髓压迫症(MSCC)是一种肿瘤急症,通常需要紧急治疗;但尚不清楚能否在异地放疗机构对放射治疗(RT)进行最佳管理。
回顾了连续的MSCC患者的病历,这些患者分别在现场医院放疗科(2008年至2012年)或异地放疗中心(2012 - 2015年)接受单纯放疗。采用χ检验或Fisher精确检验对各组患者的临床参数进行比较,同时采用对数秩检验比较生存曲线。主要终点是随时间推移的行走率、总生存率和癌症特异性生存率。
共确定45例患者,其中19例在医院科室现场治疗,26例在异地放疗中心治疗,中位随访时间分别为42天和48.5天。两个时期的随时间推移的行走率、总生存率和癌症特异性生存率无显著差异。与在异地中心治疗的患者相比,在医院治疗的患者更有可能在会诊当天开始治疗(“同时诊断并治疗”)(79%对27%,p = 0.006),且更有可能未完成治疗(26%对4%,p = 0.029)。
MSCC患者在异地放疗中心治疗是可行的,其结果与在医院治疗相似。知识进展:这是文献中第一项比较MSCC现场放疗和异地放疗结果的研究。